crivit
: bzgl. des shareholders rights plan (poison pill)
Savient jumps 14% after earnings report
BOSTON (MarketWatch) -- Shares of Savient Pharmaceuticals SVNT +15.95% jumped 14% to 66 cents a share on Wednesday after the biotech group posted a narrowed second-quarter loss. The stock has risen 8% over the last 30 days but has plunged 70% since the beginning of the year. Earlier this week, Savient adopted a shareholders rights plan to deter a possible hostile takeover by stakeholder Tang Capital Partners. Earlier this year, Tang had asserted that Savient was insolvent. On Wednesday, Savient stated it ended the second quarter with $142.2 million in cash and short-term securities. Savient's revenues largely come from its recently approved gout drug Krystexxa, which had sales of $4 million for the second quarter.
Aus der heutige Sicht, sieht es doch sehr attraktiv aus. IMO Bin gespannt. GLTA ;)
Bristol-Myers Squibb Co. and Novartis AG both looked at acquiring Savient and passed because of concern about price, according to two people with knowledge of the matter, who declined to be identified because the talks are private. The board of directors will continue to “evaluate strategic alternatives,” Savient said in a statement today.
Ein Auszug (-das passt ja zur News vom Freitag!-):
...Pharmalot: Any other milestones coming up? Ferrari: We’re expecting to hear back from the CHMP in Europe over the next couple of weeks on an opinion. That will be a milestone...
Wird wohl der nächste Schritt:
...Pharmalot: And how is the partnership hunt going? Ferrari: We’re looking for a partner in Europe and the rest of the world. There are a number of companies that have expressed interest and we’re in active discussions. We don’t want to go it alone in Europe. It would have cost us $30 million or more to go forward in Europe at a time when we were battling on a lot of fronts. But right now, we have two years’ worth of cash. And we’re not under any pressure to raise any more. But we think any partnership ex-US will bring us some good revenues, including what we believe will bring upfront payments and royalties. Right now I think we’re in a pretty good spot...
Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout
Thread abonnieren
